| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5912013 | VALIDUS PHARMS | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
Jun, 2016
(7 years ago) | |
| US6977253 | VALIDUS PHARMS | Methods for the treatment of bipolar disorder using carbamazepine |
May, 2024
(20 days from now) | |
Equetro is owned by Validus Pharms.
Equetro contains Carbamazepine.
Equetro has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Equetro are:
- US5912013
Equetro was authorised for market use on 10 December, 2004.
Equetro is available in capsule, extended release;oral dosage forms.
Equetro can be used as the recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response..
The generics of Equetro are possible to be released after 19 May, 2024.
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 10 December, 2004
Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
EQUETRO family patents
